EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

YME1L1 Dysfunction Associated With 3‐Methylglutaconic Aciduria

Anthi Demetriadou iD, Olga Grafakou iD, Theodoros Georgiou, Daniela Burska iD, Anna Malekkou iD, Jana Krizova iD, Efstathia Paramera, Gavriella Mavrikiou iD, Maria Dionysiou, Athina Theodosiou iD, Carolina Sismani iD, Violetta Anastasiadou iD und 5 weitere

Journal of Inherited Metabolic Disease · 2025

DOI: 10.1002/jimd.70029 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Anthi Demetriadou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus. Hauptthemen laut MEDLINE: Metabolism, Inborn Errors, Metalloendopeptidases, Mitochondrial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Cyprus Institute of Neurology and Genetics, Ministry of Health Czech Republic, General University Hospital Prague.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

3‐methylglutaconic aciduria (3‐MGCA) is a biochemical finding in a diverse group of inherited metabolic disorders. Conditions manifesting 3‐MGCA are classified into two major categories, primary and secondary. Primary 3‐MGCAs involve two inherited enzymatic deficiencies affecting leucine catabolism, whereas secondary 3‐MGCAs comprise a larger heterogeneous group of conditions that have in common compromised mitochondrial energy metabolism. Here, we report 3‐MGCA in two siblings presenting with sensorineural hearing loss and neurological abnormalities associated with a novel, homozygous missense variant (c.1999C>G, p.Leu667Val) in the YME1L1 gene which encodes a mitochondrial ATP‐dependent metalloprotease. We show that the identified variant results in compromised YME1L1 function, as evidenced by abnormal proteolytic processing of substrate proteins, such as OPA1 and PRELID1. Consistent with the aberrant processing of the mitochondrial fusion protein OPA1, we demonstrate enhanced mitochondrial fission and fragmentation of the mitochondrial network in patient‐derived fibroblasts. Furthermore, our results indicate that YME1L1 L667V is associated with attenuated activity of rate‐limiting Krebs cycle enzymes and reduced mitochondrial respiration, which may explain the build‐up of 3‐methylglutaconic and 3‐methylglutaric acid due to the diversion of acetyl‐CoA, not efficiently processed in the Krebs cycle, towards the formation of 3‐methylglutaconyl‐CoA, the precursor of these metabolites. In summary, our findings classify YME1L1 deficiency as a new type of secondary 3‐MGCA, thus expanding the genetic landscape and facilitating the diagnosis of inherited metabolic disorders featuring this biochemical phenotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolism, Inborn ErrorsMetalloendopeptidasesMitochondrial ProteinsChildFemaleHumansMaleFibroblastsHearing Loss, SensorineuralMitochondriaMitochondrial DynamicsMutation, MissenseSiblingsGlutarates

Stichwörter der Autor:innen

3‐methylglutaconic aciduriaYME1L1inherited metabolic disordersmitochondrial disordersmitochondrial dysfunctionmitochondrial fragmentation

Substanzen

3-methylglutaconic acidMetalloendopeptidasesMitochondrial ProteinsGlutarates

Autor:innen und Institutionen

  • Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • Department of Paediatrics, Inborn Errors of Metabolism Clinic, Archbishop Makarios III Hospital, State Health Services Organisation (SHSO), Nicosia, Cyprus.
  • Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
  • Neolab SA Medical Laboratory, Athens, Greece.
  • Cytogenetics and Genomics Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • Karaiskakio Foundation, Nicosia Cyprus and Archbishop Makarios III Hospital, State Health Services Organisation (SHSO), Nicosia, Cyprus.

ORCID-Profile: Anthi Demetriadou, Olga Grafakou, Daniela Burska, Anna Malekkou, Jana Krizova, Gavriella Mavrikiou, Athina Theodosiou, Carolina Sismani, Violetta Anastasiadou, Hana Hansikova, Anthi Drousiotou, Petros P Petrou

Förderung

  • The Cyprus Institute of Neurology and Genetics
  • Ministry of Health Czech Republic
  • General University Hospital Prague
  • Charles University
  • Univerzita Karlova v Praze

Zitieren

APA

Demetriadou, A., Grafakou, O., Georgiou, T., Burska, D., Malekkou, A., Krizova, J., Paramera, E., Mavrikiou, G., Dionysiou, M., Theodosiou, A., Sismani, C., Anastasiadou, V., Ioannou, I., Papakonstantinou, E., Hansikova, H., Drousiotou, A., & Petrou, P. P. (2025). YME1L1 Dysfunction Associated With 3‐Methylglutaconic Aciduria. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70029

Vancouver

Demetriadou A, Grafakou O, Georgiou T, Burska D, Malekkou A, Krizova J, et al. YME1L1 Dysfunction Associated With 3‐Methylglutaconic Aciduria. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70029

BibTeX
@article{Demetriadou2025,
  author = {Demetriadou, Anthi and Grafakou, Olga and Georgiou, Theodoros and Burska, Daniela and Malekkou, Anna and Krizova, Jana and Paramera, Efstathia and Mavrikiou, Gavriella and Dionysiou, Maria and Theodosiou, Athina and Sismani, Carolina and Anastasiadou, Violetta and Ioannou, Ioannis and Papakonstantinou, Evangelos and Hansikova, Hana and Drousiotou, Anthi and Petrou, Petros P},
  title = {YME1L1 Dysfunction Associated With 3‐Methylglutaconic Aciduria},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  doi = {10.1002/jimd.70029}
}
Kostenlos starten →